Search results for "double-blind method"

showing 10 items of 631 documents

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study…

2020

BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.METHODS: In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [&l…

RESISTANT STARCHPlacebo-controlled study030204 cardiovascular system & hematology0302 clinical medicineLife Tables030212 general & internal medicine11 Medical and Health Sciencesmedia_commonRISKAspirineducation.field_of_studyAnti-Inflammatory Agents Non-SteroidalLOW-DOSE ASPIRINGeneral MedicineLynch syndrome3. Good healthIntention to Treat AnalysisAnti-Inflammatory Agents Non-Steroidal/adverse effectsmedicine.drugCHEMOPREVENTIONmedicine.medical_specialtyHeterozygote3122 CancersPopulationNEOPLASIAAspirin/adverse effectsPlaceboCAPP2 InvestigatorsMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal medicineGeneral & Internal MedicineColorectal Neoplasms Hereditary Nonpolyposis/geneticsBENEFITSmedicinemedia_common.cataloged_instanceHumansEuropean unioneducationProportional Hazards ModelsIntention-to-treat analysisCancer preventionAspirinbusiness.industryMORTALITY3126 Surgery anesthesiology intensive care radiologymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisbusinessFollow-Up Studies
researchProduct

Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled…

2017

Dysbalance in gut microbiota has been linked to increased microbial translocation, leading to chronic inflammation in HIV-patients, even under effective HAART. Moreover, microbial translocation is associated with insufficient reconstitution of CD4+T cells, and contributes to the pathogenesis of immunologic non-response. In a double-blind, randomised, placebo-controlled trial, we recently showed that, compared to placebo, 12 weeks treatment with probiotic Saccharomyces boulardii significantly reduced plasma levels of bacterial translocation (Lipopolysaccharide-binding protein or LBP) and systemic inflammation (IL-6) in 44 HIV virologically suppressed patients, half of whom (n = 22) had immun…

RNA virusesMale0301 basic medicinePlacebo-controlled studylcsh:MedicineHIV InfectionsGut floraPathology and Laboratory MedicineSystemic inflammationlaw.inventionPlacebosProbiotic0302 clinical medicineImmunodeficiency ViruseslawMedicine and Health SciencesMedicinelcsh:ScienceImmune ResponseMultidisciplinarybiologyMicrobiotaGenomicsMiddle AgedProbiòticsBacterial PathogensIntestinesSaccharomyces boulardiiMedical MicrobiologyViral PathogensVirusesFemale030211 gastroenterology & hepatologyPathogensmedicine.symptomResearch ArticleSaccharomyces boulardiiAdultImmunologyMicrobial GenomicsMicrobiologySaccharomyces03 medical and health sciencesSigns and SymptomsImmune systemDouble-Blind MethodDiagnostic MedicineRetrovirusesGeneticsVIH (Virus)HumansMicrobiomeMicrobial PathogensInflammationClostridiumBacteriabusiness.industryProbioticsGut BacteriaLentivirusLachnospiraceaelcsh:ROrganismsFungiBiology and Life SciencesHIVbiology.organism_classificationYeast030104 developmental biologyImmunologylcsh:QMicrobiomebusinessPLoS ONE
researchProduct

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpo…

2009

Hypertension guidelines advise aggressive blood pressure (BP) lowering in patients with diabetes or high cardiovascular risk, but supporting evidence is limited. We analysed the impact of BP on cardiovascular events in well treated high-risk patients enrolled in a large clinical trial (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Twenty-five thousand five hundred and eighty-eight patients with atherosclerotic disease or diabetes with organ damage, tolerant to angiotensin-converting enzyme inhibitors, were randomized to ramipril, telmisartan or both. We related the primary composite outcome and its components to: baseline SBP; SBP changes from baseline to…

RamiprilMalemedicine.medical_specialtyPhysiologyAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineInternal MedicinemedicineHumansTelmisartanRisk factorAntihypertensive AgentsAgedVascular diseasebusiness.industryMiddle Agedmedicine.diseasePrognosisAngiotensin IISurgeryClinical trialBlood pressureTreatment OutcomeHypertensionCardiologyBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

2022

Abstract Aims The role of diuretics in patients with intermediate-risk pulmonary embolism (PE) is controversial. In this multicentre, double-blind trial, we randomly assigned normotensive patients with intermediate-risk PE to receive either a single 80 mg bolus of furosemide or a placebo. Methods and results Eligible patients had at least a simplified PE Severity Index (sPESI) ≥1 with right ventricular dysfunction. The primary efficacy endpoint assessed 24 h after randomization included (i) absence of oligo-anuria and (ii) normalization of all sPESI items. Safety outcomes were worsening renal function and major adverse outcomes at 48 hours defined by death, cardiac arrest, mechanical ventil…

Randomizationmedicine.medical_treatmentVentricular Dysfunction Right[SDV]Life Sciences [q-bio]Critical Care and Intensive Care MedicinePlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawFurosemidemedicineHumansDiureticsbusiness.industryFurosemideGeneral Medicinemedicine.diseasePulmonary embolismBlood pressureTreatment OutcomeAnesthesiaAcute DiseaseDiureticBolus (digestion)Cardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double‐blind, multi‐center cross‐over non‐inferiority s…

2018

Intravenous immunoglobulin (IVIg) is the gold-standard for maintenance treatment of multifocal motor neuropathy (MMN). This phase III, randomised, double-blind, multi-centre, active-control, crossover study, aimed to evaluate the non-inferiority of IqYmune® relative to Kiovig®, primarily based on efficacy criteria. Twenty-two adult MMN patients, treated with any brand of IVIg (except Kiovig® or IqYmune®) at a stable maintenance dose within the range of 1 to 2 g/kg every 4 to 8 weeks, were randomised to receive either Kiovig® followed by IqYmune®, or IqYmune® followed by Kiovig®. Each product was administered for 24 weeks. The primary endpoint was the difference between IqYmune® and Kiovig® …

Research ReportIVIgAdultMalemedicine.medical_specialtymultifocal motor neuropathyEquivalence Trials as Topiclaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicineOutcome Assessment Health CaremedicineClinical endpointHumansImmunologic FactorsMotor Neuron DiseaseAgedCross-Over StudiesMaintenance dosebusiness.industryGeneral NeuroscienceImmunoglobulins IntravenousResearch Reportsclinical trialMiddle AgedHaemolysismedicine.diseaseCrossover studyConfidence intervalTolerability030220 oncology & carcinogenesisFemaleNeurology (clinical)businessimmunoglobulin030217 neurology & neurosurgeryMultifocal motor neuropathyJournal of the Peripheral Nervous System
researchProduct

Oxidative stress in asphyxiated term infants resuscitated with 100% oxygen

2003

Although room air is adequate for resuscitating asphyxiated newborn infants, guidelines recommend using 100% oxygen. Hyperoxemia, as has been noted in animal studies, could cause delayed breathing, increased oxygen consumption, and disordered cerebral circulation. In addition, 100% oxygen has caused prolonged oxidation of blood glutathione in neonates. In this study, 51 asphyxiated neonates born at term were randomly assigned to resuscitation with room air (RAR) and 55 to resuscitation with 100% oxygen (OxR). The goal was to learn whether using oxygen for resuscitation triggers oxidative stress. Critical criteria were the Apgar score, the time of the first cry, and sustained respiration. Si…

ResuscitationResuscitationGlutathione reductasemedicine.disease_causechemistry.chemical_compoundDouble-Blind MethodmedicineHumansAcidosisAsphyxiachemistry.chemical_classificationAsphyxia NeonatorumGlutathione DisulfideSuperoxide Dismutasebusiness.industryGlutathione peroxidaseInfant NewbornOxygen Inhalation TherapyObstetrics and GynecologyApneaHyperoxemiaGeneral MedicineGlutathioneCarbon DioxideFetal BloodGlutathioneOxygenOxidative StressGlutathione ReductasechemistryAnesthesiaPediatrics Perinatology and Child HealthBreathingApgar ScoreRoom air distributionApgar scoremedicine.symptombusinessOxidative stressThe Journal of Pediatrics
researchProduct

Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double-blind, randomized controll…

2015

OBJECTIVE: The aim of this study was to compare crestal bone-level changes, soft tissue parameters and implant success and survival between small-diameter implants made of titanium/zirconium (TiZr) alloy or of Grade IV titanium (Ti) in edentulous mandibles restored with removable overdentures. MATERIALS AND METHODS: This was a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann bone-level implants (diameter 3.3 mm), one of Ti Grade IV (control) and one of TiZr (test), in the interforaminal region. Implants were loaded after 6-8 weeks and removable Locator-retained overdentures were placed within 2 weeks of l…

RoxolidMaleSmall diameterSLActive surfaceDentistrychemistry.chemical_elementMandibleCONVENTIONAL COMPLETE DENTURESlaw.inventionDouble blindRETROSPECTIVE EVALUATION IMPLANTDouble-Blind MethodRandomized controlled triallawMARGINAL BONE LOSSHumansJaw EdentulousMedicineMANDIBULAR 2-IMPLANT OVERDENTURES610 Medicine & healthAgedDental ImplantsTitaniumPATIENT SATISFACTIONTitanium/zirconiumSTRESS-DISTRIBUTIONbusiness.industryDental Implantation Endosseoustechnology industry and agricultureWITHIN-SUBJECT COMPARISONSSoft tissueDIFFERENT LOADING PROTOCOLSDenture Overlayequipment and suppliesTitanium zirconiumddc:617.6Treatment OutcomeDental Prosthesis DesignchemistryImplant typesedentulousFemaleZirconiumImplantFINITE-ELEMENT-ANALYSISOral SurgerybusinessDental AlloysTitaniumClinical Oral Implants Research
researchProduct

Small-diameter titanium grade IV and titanium-zirconium implants in edentulous mandibles: five-year results from a double-blind, randomized controlle…

2015

BACKGROUND The aim of this study was to compare the 5-year survival and success rates of 3.3 mm dental implants either made from titanium-zirconium (TiZr) alloy or from Grade IV titanium (Ti Grade IV) in mandibular implant-based removable overdentures. METHODS The core study had a follow-up period of 36 months and was designed as a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann Bone Level implants (diameter 3.3 mm, SLActive®), one of TiZr (test) and one of Ti Grade IV (control), in the interforaminal region. This follow-up study recruited patients from the core study and evaluated the plaque and sulcus …

RoxolidSmall diameterSplit-mouthDentistrychemistry.chemical_element610 Medicine & healthMandiblelaw.inventionTiZrDouble blindstomatognathic systemRandomized controlled trialDouble-Blind MethodlawOverdenturesAlloysMedicineHumansJaw Edentulous610 Medicine & healthGeneral DentistrySurvival rateOrthodonticsDental ImplantsTitaniumbusiness.industryDentistry(all)Ti Grade IVDental Implantation Endosseoustechnology industry and agricultureSLActiveequipment and suppliesDenture OverlayTitanium zirconiumddc:617.6stomatognathic diseaseschemistryDental Prosthesis DesignOral and maxillofacial surgeryImplantZirconiumbusinessTitaniumFollow-Up StudiesResearch Article
researchProduct

Assessment of the capacity of a pyrophosphate-based mouth rinse to inhibit the formation of supragingival dental calculus. a randomized double-blind …

2019

Background This study aimed to analyze the efficacy of an anti-calculus mouth rinse and its possible adverse effects on the mucosa and teeth. Material and Methods This randomized double-blind placebo-controlled clinical trial included 40 patients with treated and managed periodontal disease, all with a history of rapid calculus formation. Patients used a pyrophosphate-based test mouth rinse (B) or a placebo (A). A range of parameters were measured for: saliva (saliva flow, pH and chemical composition); calculus (Volpe-Manhold [V-M] index, weight, and volume); adverse effects on mucosa and teeth; and the patients’ subjective perceptive of mouth rinse efficacy. Results The test mouth rinse B …

SalivaMouthwashesPlacebolaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind Methodstomatognathic systemRandomized controlled triallawDentifriceCalculusHumansMedicineDental CalculusAdverse effectGeneral DentistryDentifricesOral Medicine and Pathologybusiness.industryResearchCalculus (dental)030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDiphosphatesstomatognathic diseasesOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASUreaUric acidSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vacc…

2010

13-valent pneumococcal conjugate vaccine (PCV13) was compared to PCV7 in infants administered 4 doses. For the 7 common serotypes, PCV13- and PCV7-elicited responses showed comparable percent responders achieving 0.35mug/mL IgG threshold (exception 6B, 77.5% versus 87.1%, respectively) and OPA titers of 1:8; IgGs were lower than PCV7 but functional responses were generally comparable. For the 6 additional serotypes, PCV13-elicited IgG and functional OPA responses were notably greater than PCV7. The toddler dose boosted immune responses. Vaccines were comparable with regard to safety. PCV13 should be as effective as PCV7 in preventing pneumococcal disease caused by the common serotypes and m…

SerotypeMaleHeptavalent Pneumococcal Conjugate Vaccinemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal Vaccinesstomatognathic systemDouble-Blind MethodGermanyStreptococcus pneumoniaemedicineHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ScheduleVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPneumococcal infectionsInfectious DiseasesImmunizationImmunoglobulin GImmunologyMolecular MedicineFemalebusinessmedicine.drugVaccine
researchProduct